HEMGENIX®
Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.
Key Publications
Publications
Gene therapy with etranacogene dezaparvovec for hemophilia B
Pipe SW, Leebeek FWG, Recht M, et al. N Engl J Med. 2023Request | Ask a Question | View Article
Posters
Four-year results of etranacogene dezaparvovec in haemophilia B patients with pre-existing AAV5 neutralising antibodies: Phase 3 HOPE-B trial
Please see full prescribing information for HEMGENIX
Four-year results of etranacogene dezaparvovec in haemophilia B patients without pre-existing AAV5 neutralising antibodies: Phase 3 HOPE-B trial
Please see full prescribing information for HEMGENIX
Natural history of AAV5 neutralising antibodies in adults with haemophilia B during ≥6-month screening and lead-in to the HOPE-B trial with etranacogene dezaparvovec gene therapy
Please see full prescribing information for HEMGENIX
Etranacogene dezaparvovec-drlb hemophilia B gene therapy Phase 2b trial final results: Stable and durable FIX level expression over 5 years
Please see full prescribing information for HEMGENIX
IX-TEND: A Phase IV Observational, Long-term Follow-up Study on the Safety and Efficacy of Etranacogene Dezaparvovec in Patients with Hemophilia B
Please see full prescribing information for HEMGENIX
First Real-world Experience Administering Etranacogene Dezaparvovec Gene Therapy for People with Hemophilia B
Please see full prescribing information for HEMGENIX
Sustained efficacy and safety 3 years following infusion with etranacogene dezaparvovec in adults with severe or moderately severe hemophilia B in the Phase 3 HOPE-B clinical trial
Please see full prescribing information for HEMGENIX
HIV Comorbid Infection and Liver-Directed AAV-Based Gene Therapy in Adults with Severe and Moderately Severe Hemophilia B: Efficacy and Safety Results from Phase 2b and the Pivotal Phase 3 HOPE-B Trials 3 Years after Administration of a Single Dose of Etranacogene Dezaparvovec
Please see full prescribing information for HEMGENIX
Adult Patients With Hemophilia B and With a History of Chronic HCV/HBV Infection Receiving Liver Directed Gene Therapy Demonstrated Long-Term Bleeding Protection And Sustained FIX Activity: Efficacy and Safety Results 3 Years After Administration of a Single Dose of Etranacogene Dezaparvovec
Please see full prescribing information for HEMGENIX
Management of Infusion Reactions: Lessons from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec in Adults with Hemophilia B
Please see full prescribing information for HEMGENIX
Improvements in health-related quality of life in adults with severe or moderately severe hemophilia B after receiving etranacogene dezaparvovec gene therapy
Please see full prescribing information for HEMGENIX
Analysis of elevated alanine transaminase in HOPE B, a Phase 3 recombinant adeno associated viral 5 gene therapy trial in people with haemophilia B
Please see full prescribing information for HEMGENIX
